Albireo Pharma (ALBO) Up in Light Trading for August 4

Equities Staff  |

Shares of Albireo Pharma Inc (NASDAQ:ALBO) traded 10.71% higher on August 4 to close at $23.57.

208,805 were traded today. Their current average 30 day volume is 215,086 shares.

Albireo Pharma lost 8.59% year-to-date in 2022.

The company expects its next earnings on 2022-08-15.

For technical charts, analysis, and more on Albireo Pharma visit the company profile.

About Albireo Pharma Inc

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

To get more information on Albireo Pharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Albireo Pharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content